CN1205205A - 吡唑并吡啶化合物的用途 - Google Patents
吡唑并吡啶化合物的用途 Download PDFInfo
- Publication number
- CN1205205A CN1205205A CN97125378A CN97125378A CN1205205A CN 1205205 A CN1205205 A CN 1205205A CN 97125378 A CN97125378 A CN 97125378A CN 97125378 A CN97125378 A CN 97125378A CN 1205205 A CN1205205 A CN 1205205A
- Authority
- CN
- China
- Prior art keywords
- group
- alkyl
- low
- carboxyl
- carbamoyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Abstract
Description
剂量(毫克/公斤) | 排泄量(%) |
1 | 153 |
Claims (8)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB919107513A GB9107513D0 (en) | 1991-04-10 | 1991-04-10 | Pyrazolopyridine compound and processes for preparation thereof |
GB9107513.5 | 1991-04-10 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN92103372A Division CN1041203C (zh) | 1991-04-10 | 1992-04-09 | 吡唑并吡啶化合物的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1205205A true CN1205205A (zh) | 1999-01-20 |
CN100508975C CN100508975C (zh) | 2009-07-08 |
Family
ID=10692949
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB971253781A Expired - Lifetime CN100508975C (zh) | 1991-04-10 | 1992-04-09 | 吡唑并吡啶化合物的用途 |
CN92103372A Expired - Lifetime CN1041203C (zh) | 1991-04-10 | 1992-04-09 | 吡唑并吡啶化合物的制备方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN92103372A Expired - Lifetime CN1041203C (zh) | 1991-04-10 | 1992-04-09 | 吡唑并吡啶化合物的制备方法 |
Country Status (23)
Country | Link |
---|---|
US (1) | US5234930A (zh) |
EP (1) | EP0516941B1 (zh) |
JP (2) | JP2546470B2 (zh) |
KR (1) | KR100248700B1 (zh) |
CN (2) | CN100508975C (zh) |
AT (1) | ATE146473T1 (zh) |
AU (1) | AU653007B2 (zh) |
CA (1) | CA2065644C (zh) |
DE (1) | DE69215965T2 (zh) |
DK (1) | DK0516941T3 (zh) |
ES (1) | ES2095976T3 (zh) |
FI (1) | FI100969B (zh) |
GB (1) | GB9107513D0 (zh) |
GR (1) | GR3022113T3 (zh) |
HU (2) | HU214871B (zh) |
IE (1) | IE921086A1 (zh) |
IL (1) | IL101544A (zh) |
MX (1) | MX9201672A (zh) |
NO (1) | NO300271B1 (zh) |
RU (1) | RU2069662C1 (zh) |
SG (1) | SG43917A1 (zh) |
TW (1) | TW205550B (zh) |
UA (1) | UA27252C2 (zh) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5541213A (en) * | 1993-06-24 | 1996-07-30 | Eisai Co., Ltd. | Propenoic acid derivatives diazole propenoic acid compounds which have useful pharmaceutical utility |
KR100386542B1 (ko) * | 1993-12-29 | 2003-10-11 | 후지사와 야꾸힝 고교 가부시키가이샤 | 피라졸로피리딘아데노신길항제 |
DE69731948D1 (de) * | 1996-04-25 | 2005-01-20 | Fujisawa Pharmaceutical Co | Mittel zur vorbeugung und heilung ischämischer darmlesion und ileus |
AUPO111096A0 (en) * | 1996-07-18 | 1996-08-08 | Fujisawa Pharmaceutical Co., Ltd. | New compound |
WO1998041237A1 (fr) * | 1997-03-18 | 1998-09-24 | Fujisawa Pharmaceutical Co., Ltd. | Medicaments pour la prevention et la therapie de l'hyperphosphatemie |
CA2333947C (en) * | 1998-06-01 | 2010-09-21 | Fujisawa Pharmaceutical Co., Ltd. | Pyrazolopyridine compounds as adenosine a1 antagonist for male sterility |
US20040152659A1 (en) * | 1999-05-12 | 2004-08-05 | Fujisawa Pharmaceutical Co. Ltd. | Method for the treatment of parkinson's disease comprising administering an A1A2a receptor dual antagonist |
PE20020506A1 (es) * | 2000-08-22 | 2002-07-09 | Glaxo Group Ltd | Derivados de pirazol fusionados como inhibidores de la proteina cinasa |
WO2002048147A2 (en) * | 2000-12-15 | 2002-06-20 | Glaxo Group Limited | Pyrazolopyridines |
AU2002239348A1 (en) * | 2000-12-15 | 2002-06-24 | Glaxo Group Limited | Pyrazolopyridine derivatives |
AU2002248531A1 (en) * | 2001-03-08 | 2002-09-24 | Smithkline Beecham Corporation | Pyrazolopyriadine derivatives |
JP2004525150A (ja) * | 2001-03-30 | 2004-08-19 | スミスクライン ビーチャム コーポレーション | 治療用化合物としてのピラゾロピリジン類の使用 |
US7034030B2 (en) * | 2001-03-30 | 2006-04-25 | Smithkline Beecham Corporation | Pyralopyridines, process for their preparation and use as therapeutic compounds |
ATE332301T1 (de) * | 2001-04-10 | 2006-07-15 | Smithkline Beecham Corp | Antivirale pyrazolopyridin verbindungen |
ES2242028T3 (es) | 2001-04-27 | 2005-11-01 | Smithkline Beecham Corporation | Derivados de pirazolo(1,5-a)piridina. |
AUPR548601A0 (en) * | 2001-06-06 | 2001-06-28 | Fujisawa Pharmaceutical Co., Ltd. | Pyrazolopyrazinecompound and pharmaceutical use thereof |
HUP0400266A2 (hu) * | 2001-06-21 | 2004-08-30 | Smithkline Beecham Corp. | Imidazo[1,2-a]piridin-származékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk herpeszvírus-fertőzések megelőzésére vagy kezelésére |
US20040214834A1 (en) * | 2001-09-07 | 2004-10-28 | Kristjan Gudmunsson | Pyrazolo-pyridines for the treatment of herpes infections |
JP2005508955A (ja) * | 2001-10-05 | 2005-04-07 | スミスクライン ビーチャム コーポレーション | ヘルペスウイルス感染の治療で使用されるためのイミダゾ−ピリジン誘導体 |
AU2002357740A1 (en) * | 2001-12-11 | 2003-06-23 | Smithkline Beecham Corporation | Pyrazolo-pyridine derivatives as antiherpes agents |
WO2004033454A1 (en) * | 2002-10-03 | 2004-04-22 | Smithkline Beecham Corporation | Therapeutic compounds based on pyrazolopyridine derivatives |
JP5352452B2 (ja) * | 2006-06-06 | 2013-11-27 | メディシノバ, インコーポレイテッド | 置換ピラゾロ[1,5−a]ピリジン化合物およびその使用方法 |
US9572528B1 (en) | 2012-08-06 | 2017-02-21 | Los Angeles Biomedical Research Insitute at Harbor-UCLA Medical Center | Monitor for SIDS research and prevention |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4925849A (en) * | 1987-06-15 | 1990-05-15 | Fujisawa Pharmaceutical Company, Ltd. | Pharmaceutically useful pyrazolopyridines |
GB8901423D0 (en) * | 1989-01-23 | 1989-03-15 | Fujisawa Pharmaceutical Co | Pyrazolopyridine compound and processes for preparation thereof |
-
1991
- 1991-04-10 GB GB919107513A patent/GB9107513D0/en active Pending
-
1992
- 1992-04-02 TW TW081102547A patent/TW205550B/zh active
- 1992-04-02 AU AU13988/92A patent/AU653007B2/en not_active Expired
- 1992-04-03 IE IE108692A patent/IE921086A1/en not_active IP Right Cessation
- 1992-04-07 FI FI921522A patent/FI100969B/fi not_active IP Right Cessation
- 1992-04-08 AT AT92106028T patent/ATE146473T1/de active
- 1992-04-08 SG SG1996005302A patent/SG43917A1/en unknown
- 1992-04-08 ES ES92106028T patent/ES2095976T3/es not_active Expired - Lifetime
- 1992-04-08 DK DK92106028.1T patent/DK0516941T3/da active
- 1992-04-08 EP EP92106028A patent/EP0516941B1/en not_active Expired - Lifetime
- 1992-04-08 DE DE69215965T patent/DE69215965T2/de not_active Expired - Lifetime
- 1992-04-09 CN CNB971253781A patent/CN100508975C/zh not_active Expired - Lifetime
- 1992-04-09 NO NO19921413A patent/NO300271B1/no not_active IP Right Cessation
- 1992-04-09 JP JP4088735A patent/JP2546470B2/ja not_active Expired - Lifetime
- 1992-04-09 HU HU9201213A patent/HU214871B/hu unknown
- 1992-04-09 CN CN92103372A patent/CN1041203C/zh not_active Expired - Lifetime
- 1992-04-09 IL IL10154492A patent/IL101544A/en not_active IP Right Cessation
- 1992-04-09 KR KR1019920005893A patent/KR100248700B1/ko not_active IP Right Cessation
- 1992-04-09 RU SU5011507/04A patent/RU2069662C1/ru active
- 1992-04-09 US US07/866,215 patent/US5234930A/en not_active Expired - Lifetime
- 1992-04-09 CA CA002065644A patent/CA2065644C/en not_active Expired - Lifetime
- 1992-04-10 MX MX9201672A patent/MX9201672A/es unknown
-
1993
- 1993-06-18 UA UA93002532A patent/UA27252C2/uk unknown
-
1995
- 1995-06-22 HU HU95P/P00354P patent/HU211680A9/hu unknown
- 1995-11-16 JP JP7298193A patent/JP2903040B2/ja not_active Expired - Fee Related
-
1996
- 1996-12-19 GR GR960403475T patent/GR3022113T3/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1205205A (zh) | 吡唑并吡啶化合物的用途 | |
CN1067067C (zh) | 杂环速激肽受体拮抗物 | |
CN100369894C (zh) | 氧化氮合酶抑制剂磷酸盐 | |
CN1149190C (zh) | 一氧化氮合成酶抑制剂 | |
JP5373405B2 (ja) | 選択的アンドロゲン受容体モジュレーター | |
JP3507494B2 (ja) | タキキニン拮抗薬 | |
JP6832946B2 (ja) | キナーゼ阻害剤およびその中間体の調製方法 | |
CN1129941A (zh) | 取代的氮杂二氢亚吲哚基化合物及其制备方法 | |
CZ20013248A3 (cs) | Nové sloučeniny a prostředky jako inhibitory proteázy | |
BR112013026466B1 (pt) | Derivados de ácido 3-fenilpropiônico ramificados e o seu uso | |
AU2011340721A1 (en) | Substituted 1-benzylcycloalkylcarboxlic acids and use thereof | |
CN1311769A (zh) | 新的3-芳基-2-羟基丙酸衍生物iii | |
CN1308603A (zh) | 苯氧基乙酸衍生物和含有该衍生物的医药组合物 | |
TW200808748A (en) | Compounds and compositions as channel activating protease inhibitors | |
CN103772238B (zh) | 一类新的含酯基芳香丙酰胺化合物及其制备方法和用途 | |
CN1315320A (zh) | 作为抗糖尿病药的醚和酰胺类化合物及制备方法 | |
CN1471394A (zh) | 三肽酶抑制剂 | |
IL235097A (en) | History of insulin-2 and as protein kinase inhibitors | |
JP2009531313A (ja) | (5s)−5−[4−(5−クロロ−ピリジン−2−イルオキシ)−ピペリジン−1−スルホニルメチル]−5−メチル−イミダゾリジン−2,4−ジオン(i)の新規結晶形gおよびその中間体 | |
CN1374940A (zh) | o-茴香酰胺衍生物 | |
CN1170814C (zh) | 用于强化胆碱能活性的酰胺化合物 | |
TWI571460B (zh) | 二胺衍生物之製造方法 | |
CN1514825A (zh) | 可用于反流病的新化合物 | |
CN1288135C (zh) | 某些作为丝氨酸蛋白酶xa因子抑制剂的1-(d-环丙基甘氨酰基)-4-(哌啶-4-基)哌嗪化合物 | |
CN1353693A (zh) | 取代的苯基环己烷羧酰胺类化合物及其作为腺苷摄取抑制剂的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1048472 Country of ref document: HK |
|
ASS | Succession or assignment of patent right |
Owner name: ASTELLAS PHARMA INC. Free format text: FORMER OWNER: FUJISAWA PHARMACEUTICAL CO., LTD. Effective date: 20060512 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20060512 Address after: Tokyo, Japan Applicant after: Yamanouchi Pharma Co., Ltd. Address before: Osaka Japan Applicant before: Fujisawa Pharmaceutical Co., Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CX01 | Expiry of patent term |
Expiration termination date: 20120409 Granted publication date: 20090708 |